Tag Archives: Edward White

Aileron Therapeutics Inc (ALRN) Receives a Buy from H.C. Wainwright

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Aileron Therapeutics Inc (ALRN – Research Report), with a price target of $6.00. The company’s shares closed last Monday at $0.83, close to its 52-week

Analysts Offer Insights on Healthcare Companies: G1 Therapeutics Inc (NASDAQ: GTHX), Genocea Biosciences (NASDAQ: GNCA) and Turning Point Therapeutics Inc (NASDAQ: TPTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on G1 Therapeutics Inc (GTHX – Research Report), Genocea Biosciences (GNCA – Research Report) and Turning Point Therapeutics Inc (TPTX – Research Report)

Acceleron Pharma (XLRN) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Edward White maintained a Buy rating on Acceleron Pharma (XLRN – Research Report) today and set a price target of $68. The company’s shares closed last Monday at $44.65. White wrote: “We are lowering our price target

Arqule Inc (ARQL) Initiated with a Buy at H.C. Wainwright

In a report released today, Edward White from H.C. Wainwright initiated coverage with a Buy rating on Arqule Inc (ARQL – Research Report) and a price target of $13. The company’s shares closed last Monday at $7.97. White noted: “We

G1 Therapeutics Inc (GTHX) Gets a Buy Rating from H.C. Wainwright

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on G1 Therapeutics Inc (GTHX – Research Report), with a price target of $72. The company’s shares closed last Monday at $40. White commented: “We base

H.C. Wainwright Reaffirms Their Buy Rating on Aileron Therapeutics Inc (ALRN)

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Aileron Therapeutics Inc (ALRN – Research Report), with a price target of $6. The company’s shares closed last Monday at $0.81, close to its 52-week